Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company with a mission to bring innovative immune-based therapies to the world. Founded in 2020 and headquartered in the United States, the company is committed to becoming a leader in the development and delivery of immune-based therapies for patients worldwide.

Zenas is rapidly advancing a deep portfolio of innovative therapeutics, with a focus on autoimmune and rare diseases. The company's successful business development strategy has led to a $118.00M Series B investment at 07 November 2022, with backing from notable investors including Longitude Capital, Pivotal bioVenture Partners, Vivo Capital, Wellington Management, Fairmount Funds, Perceptive Advisors, Quan Capital, Tellus BioVentures, Xencor, and Superstring Capital.

With an experienced leadership team and a robust network of business partners, Zenas BioPharma is focused on driving operational excellence to deliver potentially transformative therapies and improve the lives of patients. For more information about Zenas BioPharma, please visit www.zenasbio.com.